Medifast Appoints Nicholas Johnson as Chief Executive Officer, Marking a New Chapter in the Company’s Evolution Medifast,the health and wellness company behind the OPTAVIA coach-guided lifestyle platform, has officially appointed Nicholas Johnson as its new Chief Executive Officer, effective June…
Uvalde CISD and Zurn Elkay Launch Major Initiative to Deliver Cleaner, Safer Drinking Water Thousands of students, teachers, staff members, and community residents in Uvalde will soon have access to cleaner, healthier, and safer drinking water thanks to a significant…
TreeFrog Therapeutics Unveils Promising Preclinical Data for TFG-001 Cell Therapy in Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotechnology company focused on developing next-generation cell therapies, has announced encouraging new preclinical findings for its lead Parkinson’s disease candidate, TFG-001, ahead…
Florida Budget Deal Restores HIV Drug Assistance Program, Reversing Controversial Cuts Thousands of Floridians living with HIV are set to regain access to critical healthcare services after state lawmakers reached a budget agreement that restores funding and eligibility for Florida’s…
Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026 Fulgent Genetics, a technology-driven life sciences company with established laboratory services and an expanding therapeutic development division, announced that the full abstract…
Natera to Present 35 Studies at ASCO 2026, Highlighting Expanding Leadership in Oncology and MRD-Guided Cancer Care Natera, a global leader in cell-free DNA and precision medicine, announced a landmark oncology data program for the 2026 American Society of Clinical…
Veracyte to Present Landmark OPTIMA and ENZAMET Trial Data at ASCO 2026, Strengthening Evidence for Genomic Testing in Breast and Prostate Cancer Care Veracyte, a leading cancer diagnostics company, has announced that new data from two major Phase III clinical…
AstraZeneca to Showcase Broad Oncology and Rare Disease Pipeline at ASCO 2026 with Late-Breaking Data Across Liver, Breast, Bladder Cancers and Amyloidosis AstraZeneca will present a comprehensive slate of late-breaking and oral presentations at the American Society of Clinical Oncology…
Future Health Challenge Awards USD 300,000 to Global Innovators Advancing Early Detection and Population Health Sensing at World Health Assembly Global health innovation took center stage in Geneva as the inaugural Future Health Challenge 2026: Building Anticipatory Health Systems through…
Enhertu® Recommended for EU Approval by CHMP for Treatment of Previously Treated HER2-Positive Metastatic Solid Tumors Enhertu® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), has received a positive recommendation for approval in the European Union for the treatment of…
ClearNote Health to Present New Multi-Cohort Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting ClearNote Health, a company focused on advancing early detection technologies for some of the most lethal cancers, announced that it will present…
Datroway® Receives U.S. FDA Approval as First TROP2-Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in Patients Not Eligible for PD-1/PD-L1 Inhibitor Therapy Daiichi Sankyo and AstraZeneca announced that Datroway (datopotamab deruxtecan-dlnk) has received approval in…